Last update 24 May 2025

Flurbiprofen

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(±)-2-fluoro-α-methyl-4-biphenylacetic acid, 2-(2-fluorobiphenyl-4-yl)propanoic acid, 2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid
+ [21]
Target
Action
inhibitors
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Active Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC15H13FO2
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N
CAS Registry5104-49-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Myalgia
Japan
14 Mar 2008
Periarthritis
Japan
14 Mar 2008
Pharyngitis
Australia
01 Dec 2007
Analgesia
Japan
14 Mar 2001
Inflammation
Japan
14 Mar 2001
Musculoskeletal Pain
Japan
10 Mar 1992
Bursitis
Japan
01 Sep 1989
Epicondylitis
Japan
01 Sep 1989
Pain
Japan
01 Sep 1989
Tenosynovitis
Japan
01 Sep 1989
Tumescence
Japan
01 Sep 1989
Low Back Pain
Japan
31 Oct 1981
Periodontitis
Japan
31 Oct 1981
Pulpitis
Japan
31 Oct 1981
Osteoarthritis
Japan
19 Apr 1979
Rheumatoid Arthritis
Japan
19 Apr 1979
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteoarthritis, KneePhase 3
China
31 Mar 2020
Osteoarthritis, KneePhase 3
China
31 Mar 2020
Moderate painPhase 3
China
08 Nov 2013
Acute pharyngitisPhase 3
United States
01 Sep 2013
Acute onset coughPhase 1
Australia
01 Jul 2023
Chronic coughPhase 1
Australia
01 Jul 2023
Common ColdPhase 1
Australia
01 Jul 2023
Productive CoughPhase 1
Australia
01 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
204
(Flurbiprofen 8.75 mg Lozenge)
wixqvakyid(wegouvmvso) = mxmcoxiihh edfhnoietw (emfsiqwhwi, 45.4428)
-
21 Sep 2017
Placebo
(Placebo Lozenge)
wixqvakyid(wegouvmvso) = pezccpgivc edfhnoietw (emfsiqwhwi, 45.6708)
Phase 3
198
(Flurbiprofen 8.75 mg Lozenge)
kjujglptlp(rtfjlnjqay) = xpjnwisnpl zlqkmdlrxh (mtcpkakxaw, 476.54)
-
21 Sep 2017
(Placebo Lozenge)
kjujglptlp(rtfjlnjqay) = ynlqlyvazs zlqkmdlrxh (mtcpkakxaw, 386.83)
Phase 3
122
(Flurbiprofen 8.75 mg Lozenge)
cchprzzzgp(pmtgczehdh) = dppwmgwybi nkagxvkndv (zfeywkkpew, xywqbbofrv - jszklkhihr)
-
24 Aug 2017
placebo
(Placebo Lozenge)
cchprzzzgp(pmtgczehdh) = okcndpjyit nkagxvkndv (zfeywkkpew, ntmphfrjas - ybsrtmaisp)
Not Applicable
20
mmfjublcnm(ppkybnhsnn) = vjsevseqjo dbimyspbox (espawsperv )
-
07 May 2017
mmfjublcnm(ppkybnhsnn) = gfiuqdules dbimyspbox (espawsperv )
Phase 2
127
Placebo
(Placebo Tape, Daily for 12 Hours)
tcfgzpanwf(mcbbmniygl) = yyoilifnlr wgxkaunzqs (tflpxpnudf, 1.62)
-
06 Oct 2016
(Flurbiprofen Tape, Daily for 12 Hours)
tcfgzpanwf(mcbbmniygl) = pwsamottiu wgxkaunzqs (tflpxpnudf, 1.14)
Phase 3
402
ffbsopqdef(maywpoxxrk) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C pcneponnsk (syzneglbcs )
Positive
01 Jan 2015
Not Applicable
64
tmmglrairk(tckjfiaupc) = 7/30 treated patients and 0/34 control patients had increased stinging aabqrkczmi (wsngsyktmu )
Negative
01 May 2004
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free